# The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)

> **NCT04712279** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Corpometria Institute** · enrollment: 294 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Ivermectin 0.6mg/kg/day
- **DRUG:** Ivermectin 1.0mg/kg/day
- **DRUG:** Placebo
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04712279
- **Lead sponsor:** Corpometria Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-25
- **Primary completion:** 2021-03-21
- **Final completion:** 2021-04-20
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712279, "The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04712279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*